MOLLIE R DESHAZO
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology BIRMINGHAM, AL NPI 1487603841
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology AL PFIZER INC. All categories
General Payments — all program years on this page
$37,287.04
- Category: General Payments
- Program years: PY2018–2024
- Record count: 220
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $14,766.50 across 61 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,960.00 | 2 |
| Consulting Fee | $2,997.50 | 2 |
| Travel and Lodging | $1,484.50 | 5 |
| Food and Beverage | $1,211.16 | 50 |
| Education | $113.34 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $6,617.63 | 23 |
| Astellas Pharma US Inc | $4,506.20 | 9 |
| Janssen Scientific Affairs, LLC | $2,997.50 | 2 |
| Acerta Pharma LLC | $190.90 | 5 |
| Merck Sharp & Dohme Corporation | $71.68 | 3 |
| Dendreon Pharmaceuticals LLC | $66.67 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $58.57 | 3 |
| E.R. Squibb & Sons, L.L.C. | $49.77 | 3 |
| Tempus AI, Inc | $47.90 | 2 |
| EISAI INC. | $44.13 | 3 |
| AIMMUNE THERAPEUTICS, INC. | $29.48 | 2 |
| Myriad Genetic Laboratories, Inc. | $25.14 | 1 |
| Gilead Sciences, Inc. | $22.85 | 1 |
| Sumitomo Pharma America, Inc. | $20.50 | 1 |
| Janssen Biotech, Inc. | $17.58 | 1 |
By program year
Records — PY2024 (61)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.